Fig. 4: Optimization of therapeutic payloads of CATP in B16F10 melanoma model.
From: Cascade amplification of therapeutic payloads for cancer immunotherapy
Six- to eight-week-old C57BL/6 mice (n = 5 per group, a cage of animal) were subcutaneously inoculated with 1 million B16F10 melanoma cells. Seven days post-inoculation, mice were intratumorally treated with PBS (Control group of basal line), or LNP encapsulating 5 µg SamRNA encoding with mouse IL-12 (IL-12), 5 µg SamRNA encoding with firefly Luciferase, and 1 µg modified mRNA encoding capsids/envelops from SFV4 (Control group of treated group); or LNP encapsulating 5 µg SamRNA encoding with mouse wild type IL-18 (wtIL-18) or mutant IL-18 (mtIL-18), 5 µg SamRNA encoding with firefly Luciferase, and 1 µg modified mRNA encoding capsids/envelops from SFV4; or LNP encapsulating 5 µg SamRNA encoding with mouse IL-12 (IL-12), 5 µg SamRNA encoding with wild type IL-18 (wtIL-18) or mutant IL-18 (mtIL-18), and 1 µg modified mRNA encoding capsids/envelops from SFV4 as indicated. Results are shown as: Tumor areas (Y-axis), Survival rates (Y-axis), and Body weight changes (Y-axis) versus days post B16F10 melanoma cell inoculation (X-axis) (a–c), respectively. The P-Values labeled was determined by a two-way ANOVA test or Comparison of Survival Curves (Kaper-myer) test.
